Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594939 | 0.93 | CYP2C9 (0.78) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL12058592 | 0.92 | CYP3A4 (0.68) | CCR2CYP3A4CYP2C9JAK1 | |
| Ilacirnon SCHEMBL29395065 | 0.89 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| Ilacirnon SCHEMBL31378455 | 0.89 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| Ilacirnon SCHEMBL125684 | 0.89 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| Ilacirnon SCHEMBL30231013 | 0.89 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| Ilacirnon SCHEMBL127113 | 0.89 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL12040695 | 0.89 | CYP3A4 (0.63) | CCR2CYP3A4CYP2C9JAK1 | |
| Ilacirnon SCHEMBL125683 | 0.89 | CCR2 (0.98) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL12594257 | 0.86 | CCR2 (0.79) | CCR2CYP3A4CYP2C9JAK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| WO-2009009740-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | CCR2 1/4885CYP3A4 1134/4885CYP2C9 1281/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CCR2 1/4885CYP3A4 1134/4885CYP2C9 1281/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CCR2 1/4885CYP3A4 1134/4885CYP2C9 1281/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.